Aberrant microglia activation causes dopaminergic neuronal loss and nitric oxide produced by microglia plays a critical role in dopaminergic neuronal degeneration. However, no study has determined if GDNF protects dopaminergic neurons via inhibiting nitric oxide generation in Parkinson's disease animal model. We report that GDNF not only reduces lipopolysaccharide-induced degeneration of dopaminergic neurons, suppresses microglia activation and nitric oxide generation, but also reverses the inhibition of phosphoinositide 3-kinase (PI3K) in dopaminergic neurons and microglia. It suggests that the neuroprotective effect of GDNF on dopaminergic neurons may be related to its suppression of microglia activation-mediated nitric oxide via releasing the inhibition of PI3K in both neurons and microglia.
Introduction
Parkinson's disease (PD) is a common neurodegenerative movement disorder. The progressively selective dopaminergic neuronal degeneration in the substantia nigra of the midbrain is a hallmark of PD pathology. Increasing evidence has suggested that neuroinflammation (Cunningham et al., 2005; Herrera et al., 2005; Hong, 2005; Jenner, 2003; McGeer et al., 2001 ) and oxidative stress (Elkon et al., 2004; Jenner, 2003) are involved in the process of dopaminergic neuronal loss. Inflammation and oxidative stress mediated by activated microglia have been known to be significant pathological features of PD (Dexter et al., 1994; Jenner and Olanow, 1998) , and that suppression of inflammation and oxidative stress from activated microglia is neuroprotective in various animal models of PD (Kotake et al., 2005; Li et al., 2005a; Liu et al., 2003; Sherer et al., 2003; Testa et al., 2005; Wu et al., 2002) .
Glial cell line-derived neurotrophic factor (GDNF) is one of the most potent neurotrophic factors for survival of dopaminergic neurons (Lin et al., 1993) . Evidence has shown that GDNF has a neuroprotective and restorative effect on the nigral dopamine system in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (Cheng et al., 1998) and 6-hydroxydopamine (6-OHDA)-induced (Aoi et al., 2000; Ding et al., 2004; Lapchak et al., 1997; Rosenblad et al., 1998 Rosenblad et al., , 1999 Yasuhara et al., 2005) animal PD models, in non-human primates (Eslamboli et al., 2003; Gash et al., 1996; Grondin et al., 2002; Kordower et al., 2000; Maswood et al., 2002; Reilly, 2001) , and by direct intraputamenal infusion in PD patients (Gill et al., 2003; Patel et al., 2005) . In contrast, clinical trials of intracerebroventricular infusion of GDNF showed different outcomes, suggesting not only the necessity of alternative delivery systems to enhance the efficacy on the target reach (Kordower et al., 1999; Lindvall and Wahlberg, 2008) , but also of further study on the signaling mechanisms of its neuroprotective effect so that the side effects can be minimized.
A series of in vitro studies has explored the signal transduction mechanisms for the neuroprotective effects of GDNF. A recent study showed the ability of GDNF to prevent microglia activation induced by β-amyloid in rabbit hippocampus (Ghribi et al., 2004) . On the other hand, the inhibition of phosphoinositide 3-kinase (PI3K) blocked GDNFmediated neuronal protection in the 6-OHDA-induced PD model (Ugarte et al., 2003) . In contrast, PI3K activation enhances the neuroprotective effects of GDNF against H 2 O 2 -induced neuronal death in PD cybrids (Onyango et al., 2005) . Furthermore, GDNF protects mesencephalic neurons by suppression of oxygen radical accumulation and caspase-dependent apoptosis in the 1-methyl-4-phenylpyridinium (MPP + ) model, which are mediated by the PI3K/Akt pathway (Ding et al., 2004; King et al., 2001; Sawada et al., 2000) . More importantly, Journal of Neuroimmunology 225 (2010) [43] [44] [45] [46] [47] [48] [49] [50] [51] 
